Praxis Precision Medicines, Inc. (PRAX) stock
PRAXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$310.90+5.71 (+1.87%)
Close on Nov 19, 2026Market cap $8.68BP/E –Yield –
Praxis Precision Medicines free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Praxis Precision Medicines's free cash flow for the twelve months ending Jun 30, 2026 was -$305.38M. For fiscal 2025 it was -$249.12M. The highest annual figure on record is -$33.52M in fiscal 2019.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$249.12M | – |
| FY2024 | Dec 31, 2024 | -$131.76M | – |
| FY2023 | Dec 31, 2023 | -$111.19M | – |
| FY2022 | Dec 31, 2022 | -$185.49M | – |
| FY2021 | Dec 31, 2021 | -$125.60M | – |
| FY2020 | Dec 31, 2020 | -$52.62M | – |
| FY2019 | Dec 31, 2019 | -$33.52M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$77.79M | – |
| Q1 FY2026 | Mar 31, 2026 | -$86.21M | – |
| Q4 FY2025 | Dec 31, 2025 | -$76.33M | – |
| Q3 FY2025 | Sep 30, 2025 | -$65.06M | – |
| Q2 FY2025 | Jun 30, 2025 | -$54.73M | – |
| Q1 FY2025 | Mar 31, 2025 | -$53.01M | – |
| Q4 FY2024 | Dec 31, 2024 | -$56.12M | – |
| Q3 FY2024 | Sep 30, 2024 | -$27.50M | – |
| Q4 FY2023 | Dec 31, 2023 | -$23.91M | – |
| Q3 FY2023 | Sep 30, 2023 | -$23.22M | – |
| Q2 FY2023 | Jun 30, 2023 | -$31.21M | – |
| Q1 FY2023 | Mar 31, 2023 | -$32.85M | – |
| Q4 FY2022 | Dec 31, 2022 | -$28.81M | – |
| Q3 FY2022 | Sep 30, 2022 | -$44.96M | – |
| Q2 FY2022 | Jun 30, 2022 | -$57.32M | – |
| Q1 FY2022 | Mar 31, 2022 | -$54.40M | – |
| Q4 FY2021 | Dec 31, 2021 | -$45.39M | – |
| Q3 FY2021 | Sep 30, 2021 | -$24.41M | – |
| Q2 FY2021 | Jun 30, 2021 | -$30.08M | – |
| Q1 FY2021 | Mar 31, 2021 | -$25.73M | – |
| Q4 FY2020 | Dec 31, 2020 | -$20.23M | – |
| Q3 FY2020 | Sep 30, 2020 | -$13.88M | – |
| Q2 FY2020 | Jun 30, 2020 | -$9.94M | – |
| Q1 FY2020 | Mar 31, 2020 | -$8.57M | – |
| Q4 FY2019 | Dec 31, 2019 | -$9.95M | – |
See a number that looks wrong?